Rebecca Jones, MD
Neurology · Phoenix, AZNPI 1104260819
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (57.5%), speaking fees and education — rather than concentrated in one kind of arrangement. 58 manufacturers reported payments, led by Banner Life Sciences, LLC at 44.4% of the total. Reporting peaked in 2024 at $18,476 and has fallen 76.0% since, to $4,443 in 2025.
Across 1,006 payments — averaging $32.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Banner Life Sciences, LLC$15K
- AbbVie$3K
- Novartis$2K
- Biogen$2K
- AstraZeneca$1K
- UCB, Inc.$1K
- plus $9K from 52 others
Across 63 payments — averaging $16,334 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$428K
- Sanofi$378K
- Genentech, Inc.$120K
- TG Therapeutics, Inc.$56K
- SK Life Science, Inc.$47K
What the payments were for
- Speaking & faculty fees$13,73942%
- Food & beverage$18,87957%
- Education$2281%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$32,847 in reported general payments places this provider in the 85th percentile of 388 neurology providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Kesimpta PenOfatumumab | 130 | $1,227,845 |
| BafiertamMonomethyl Fumarate | 51 | $394,295 |
| AustedoDeutetrabenazine | 24 | $287,546 |
| AmpyraDalfampridine | 18 | $114,314 |
| VumerityDiroximel Fumarate | 12 | $105,181 |
| BotoxOnabotulinumtoxina | 29 | $47,468 |
| Teriflunomide | 11 | $44,375 |
| Nurtec OdtRimegepant Sulfate | 26 | $43,318 |
| QuliptaAtogepant | 36 | $42,739 |
| Dalfampridine ErDalfampridine | 127 | $34,295 |
| Emgality PenGalcanezumab-Gnlm | 25 | $17,128 |
| UbrelvyUbrogepant | 15 | $14,547 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 179 | $6,900 |
| MyrbetriqMirabegron | 13 | $6,857 |
| Levetiracetam | 146 | $5,803 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo | $754 | $287,54624 claims |
| Acorda Therapeutics, IncAmpyra | $276 | $114,31418 claims |
| BiogenVumerity | $1,569 | $105,18112 claims |
| AbbVieBotox, Qulipta, Ubrelvy | $3,101 | $104,75480 claims |
| PfizerNurtec Odt | $653 | $43,31826 claims |
| Amneal Pharmaceuticals LLCPyridostigmine Bromide | $502 | $1,41024 claims |
| Upsher-smith Laboratories LLCTopiramate | $42 | $1,15153 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 388 neurology providers in Arizona.
Other neurology in Phoenix
- Barry HendinPhoenix$2.3M
- Maria OspinaPhoenix$2.1M
- Suraj MuleyPhoenix$1.7M
- Eric ErossPhoenix$778K
- Steve ChungPhoenix$685K
- Marwan SabbaghPhoenix$603K
- Kerry KnievelPhoenix$509K
- Lori TravisPhoenix$406K
- Jeffrey GittPhoenix$275K
- Todd SchwedtPhoenix$273K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.